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Skeletal muscle and bone homeostasis are regulated by members
of the myostatin/GDF-11/activin branch of the transforming
growth factor-β superfamily, which share many regulatory com-
ponents, including inhibitory extracellular binding proteins and
receptors that mediate signaling. Here, we present the results of
genetic studies demonstrating a critical role for the binding pro-
tein follistatin (FST) in regulating both skeletal muscle and bone.
Using an allelic series corresponding to varying expression levels
of endogenous Fst, we show that FST acts in an exquisitely dose-
dependent manner to regulate both muscle mass and bone den-
sity. Moreover, by employing a genetic strategy to target Fst ex-
pression only in the posterior (caudal) region of the animal, we
show that the effects of Fst loss are mostly restricted to the pos-
terior region, implying that locally produced FST plays a much
more important role than circulating FST with respect to regula-
tion of muscle and bone. Finally, we show that targeting receptors
for these ligands specifically in osteoblasts leads to dramatic in-
creases in bone mass, with trabecular bone volume fraction being
increased by 12- to 13-fold and bone mineral density being in-
creased by 8- to 9-fold in humeri, femurs, and lumbar vertebrae.
These findings demonstrate that bone, like muscle, has an enor-
mous inherent capacity for growth that is normally kept in check
by this signaling system and suggest that the extent to which this
regulatory mechanism may be used throughout the body to reg-
ulate tissue mass may be more significant than previously
appreciated.
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Myostatin (MSTN) is a transforming growth factor-β (TGF-β) superfamily member that normally acts to limit skeletal
muscle mass (1). Mice lacking MSTN exhibit dramatic increases
in skeletal muscle mass throughout the body, with individual
muscles growing to about twice the normal size. The amino acid
sequence of MSTN has been strongly conserved through evolu-
tion (2), and engineered or naturally occurring mutations in the
MSTN gene have been shown to lead to increased muscling in
many other species as well, including cattle (2–4), sheep (5), dogs
(6), rabbits (7), rats (8), swine (9), goats (10), and humans (11).
MSTN is regulated by various extracellular binding proteins,
including follistatin (FST) (12), FSTL-3 (13), GASP-1 (14), and
GASP-2 (15, 16), as well as the MSTN propeptide, which
maintains MSTN in an inactive, latent state (12, 17–19). MSTN
signals initially by binding to the activin type 2 receptors ACVR2
and ACVR2B (12, 20–22), followed by engagement of the type 1
receptors ALK4 and ALK5 (22, 23).
The function of MSTN as a negative regulator of muscle
growth is partially redundant with that of another TGF-β family
member, activin A (20, 24–27), which shares many regulatory
and signaling components with MSTN. Indeed, one of these
components, FST, was originally identified for its ability to in-
hibit secretion of follicle-stimulating hormone (FSH) by cultured
pituitary cells (28), and subsequent work showed that FST is
capable of binding and inhibiting activins (29), which are capable
of signaling to pituitary gonadotrophs to induce FSH secretion
(30). FST undergoes alternative splicing to generate two iso-
forms, the full-length FST315 and a carboxyl-terminal truncated
FST288 (31). A third form, FST303, is derived from proteolytic
cleavage of the C-terminal domain. All of the FST isoforms
contain a heparin-binding domain that mediates binding to cell-
surface proteoglycans. The presence of the C-terminal acidic tail
in FST315, however, appears to neutralize the basic residues
present in the heparin-binding domain and, as a result, FST315
binds poorly to proteoglycans and is the predominant form of
FST in the circulation. FST288, which lacks the C-terminal 26–
amino acid extension, tends to remain locally sequestered
following secretion.
Based on the existence of these multiple isoforms and their
differential biodistribution following secretion, a major question
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has been whether the mode of action of FST is primarily local,
regulating signaling by target ligands at or near the site of FST
synthesis, or whether circulating FST can influence signaling to
tissues distant from its site of synthesis. This question is relevant
not only in terms of understanding the mechanism of action of
FST but also in terms of interpreting human studies seeking
associations between circulating FST levels and various physio-
logical and pathological states. Here, we use genetic approaches
in mice to address this fundamental question with respect to the
roles of FST and this regulatory system in regulating two tissues,
skeletal muscle and bone.
Results
A number of studies have shown that FST, by binding and
inhibiting both MSTN and activin A, plays an important role in
regulating muscle growth. Specifically, we showed that transgenic
overexpression of FST in skeletal muscle leads to muscle hy-
pertrophy, consistent with inhibition of the MSTN/activin A
signaling pathway (12) and, conversely, that heterozygous loss of
Fst in mice leads not only to reductions in muscle weights (by
about 15 to 20%) but also to a shift toward oxidative fiber types,
an impairment of muscle regeneration following cardiotoxin-
induced injury, and reduced tetanic force production (25), all
consistent with overactivity of this signaling pathway. Fst−/− mice
have also been shown to have a reduced amount of muscle at
birth (32), but because mice completely lacking FST are not vi-
able, we sought to utilize mice carrying a conditional Fstflox allele
(33) to target Fst in specific cell types and regions of the body in
order to examine the effects of FST loss in tissues of adult mice.
Even after extensive backcrossing of the flox allele onto a
C57BL/6 background, we noted that mice carrying this allele (in
the absence of cre recombinase) were heavier than wild-type
mice, with total body weights of Fstflox/flox mice being increased
by 13 and 19% in males and females, respectively (SI Appendix,
Table S1). These differences in body weights reflected increased
expression of Fst from the flox allele (see below), likely resulting
from retention of the neomycin selection cassette in the targeted
locus during the construction of this mutant line (33).
The increased expression of Fst from the flox allele allowed us
to generate mice carrying various combinations of wild-type,
deletion, and flox alleles to produce an allelic series with varying
levels of Fst expression. Analysis of the gastrocnemius muscle
showed that we were able to generate Fst RNA expression levels
ranging from a 30% decrease in Fst+/− mice to 55 and 82% in-
creases in Fstflox/+ and Fstflox/flox mice, respectively (Fig. 1A).
Levels of circulating FST also generally followed the same trends,
with serum FST levels being ∼50 and 200% of wild-type levels in
Fst+/− and Fstflox/flox mice, respectively (Fig. 1B). These differences
in Fst expression levels correlated not only with total body weight
(SI Appendix, Table S1) but also with weights of individual mus-
cles, which ranged from decreases of 18 to 23% in Fst+/− mice to
increases of 29 to 48% in Fstflox/flox mice depending on the specific
muscle and sex (Fig. 1 A and C and Table 1). Fstflox/+ and Fstflox/−
mice had intermediate muscle weights, reflecting intermediate Fst
expression levels in these mice. Hence, FST acts in a dose-
dependent manner to regulate muscle mass, with an approxi-
mately linear relationship between levels of FST expression and
muscle weights.
Because Fst−/− mice die immediately after birth (32), we could
not examine the effect of complete loss of FST in adult mice. To
determine the effect of further loss of FST beyond that seen in
Fst+/− mice, we examined the effect of targeting Fstflox alleles in
specific tissues and regions of the body. In one set of experi-
ments, we examined the effect of targeting Fst in skeletal muscle
using an Myl1-cre transgene (34), which we showed to be
expressed specifically in myofibers but not in satellite cells (35).
Male mice carrying one or more Fstflox alleles in conjunction with
Myl1-cre generally had lower circulating FST levels compared
with mice lacking cre, demonstrating that myofiber-derived FST
does contribute to the circulating pool (Fig. 1B); similar trends
were seen in female mice, although the individual comparisons
were not statistically significant. Targeting Fst in myofibers resul-
ted in decreases in muscle weights in both males and females;
although the effects were relatively small, many of the differences
were statistically significant in both sexes (Fig. 1C and Table 1).
Hence, myofiber-derived FST does play some role in regulating
muscle mass.
Because the effects of targeting Fst in myofibers were small,
however, we also examined the effects of more global targeting
of Fst using the Cdx2-cre transgene, which is expressed specifi-
cally in the posterior (caudal) but not anterior (cranial) region of
the animal (36); in particular, Cdx2-cre is expressed in all cells
posterior to the umbilicus but not in any cells anterior to the
umbilicus. In order to eliminate as much Fst expression as pos-
sible, we set up crosses of Fst+/−; Cdx2-cre males with Fstflox/flox
females and analyzed Fstflox/− offspring that were either negative
or positive for Cdx2-cre. Fstflox/−; Cdx2-cre mice were viable,
which allowed us to analyze mice at adulthood. As shown in
Table 1 and Fig. 1D, muscles located in the posterior region of
Fstflox/−; Cdx2-cre mice (quadriceps and gastrocnemius), where
Cdx2-cre is expressed, exhibited significant decreases in muscle
weights that exceeded those seen in Fst+/− mice (25) (see also
Fig. 1C). These decreases were seen in both males and females
and ranged from 51 to 58% in both muscle groups compared
with Fstflox/− mice lacking Cdx2-cre.
To determine whether the decreased muscle sizes were due to
differences in fiber numbers or fiber sizes, we carried out
morphometric analysis of gastrocnemius muscles. Although we
found no significant differences in fiber number between cre-
negative and cre-positive muscles (SI Appendix, Table S2),
myofiber sizes were significantly reduced in cre-positive muscles.
As shown in Fig. 1E, the distribution of fiber sizes of Fstflox/−;
Cdx2-cre muscles had a similar overall shape to that of cre-
negative mice but was shifted significantly to smaller diameters,
with the mean fiber diameter being reduced from 45.4 μm in
Cdx2-cre–negative mice to 33.6 μm in Cdx2-cre–positive mice. For
comparison, we also carried out morphometric analysis of F66
transgenic mice, which exhibit dramatic increases in muscle mass
as a result of anMyl1-Fst transgene located on the Y chromosome
(24). As we reported previously, fiber number in the gastrocne-
mius was increased by 12% in F66 mice compared with wild-type
mice (SI Appendix, Table S2), and the distribution of fiber diam-
eters, which was slightly more spread out than in wild-type mice,
was shifted to larger diameters, with mean fiber diameter being
increased from 42.5 μm in wild-type mice to 59.7 μm in F66 mice
(Fig. 1E). Hence, by manipulating levels of Fst expression, we were
able to generate an approximately fourfold range in muscle size,
from a slightly over 50% decrease in Fstflox/−; Cdx2-cre mice to an
approximate doubling in F66 mice.
Further histological examination of muscles from Fstflox/−;
Cdx2-cre mice revealed two other effects of FST loss. First, fiber
type analysis of gastrocnemius muscles revealed a significant
shift away from glycolytic type IIb fibers and toward mixed gly-
colytic/oxidative type IIa fibers and oxidative type I fibers in
Cdx2-cre–positive muscles compared with cre-negative muscles
(Fig. 2A). This fiber type shift is consistent with that seen in
Fst+/− mice (25) but to a greater degree. In contrast, the reverse
fiber type shift was seen in F66 muscles compared with wild-type
muscles; in fact, in F66 gastrocnemius muscles, type I fibers were
completely absent, and the percentage of type IIa fibers was
reduced by nearly 50%. Hence, decreasing FST levels led to a
fiber type shift toward more oxidative fibers, and increasing FST
levels led to a fiber type shift toward more glycolytic fibers.
Second, oil red O staining of gastrocnemius sections revealed the
presence of numerous fat droplets in muscle fibers of Fstflox/−;
Cdx2-cre mice compared with cre-negative controls (Fig. 3A).
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These fat droplets were seen in the majority of muscle fibers and
not just in type I and type IIa fibers, which have been reported to
show lipid accumulation by histological examination (37).
Quantification of representative sections by fluorescence imag-
ing of Nile red–stained sections showed significantly increased
fluorescence intensity in gastrocnemius muscles isolated from
Cdx2-cre–positive compared with cre-negative mice (Fig. 3B).
We also analyzed sections of muscles isolated from F66 trans-
genic mice, which showed decreased fluorescence intensity
compared with wild-type mice. Hence, the extent of fat accu-
mulation in muscle was inversely correlated with levels of FST.
These histological changes with respect to fiber type shifts and
lipid accumulation were consistent with changes in gene ex-
pression patterns in muscles isolated from these mice. RNA-
sequencing (RNA-seq) analysis identified 399 up-regulated and
234 down-regulated transcripts in gastrocnemius muscles iso-
lated from Cdx2-cre–positive compared with cre-negative mice
(SI Appendix, Fig. S1). Among these differentially regulated
genes were ones encoding myosin heavy-chain isoforms charac-
teristic of specific fiber types (38, 39). In particular, Myh7, Myh7B,
and Myh2 were all up-regulated in Cdx2-cre–positive muscles,
consistent with increased numbers of type I and type IIa fibers, and
Mhy4 was down-regulated, consistent with decreased numbers of
type IIb fibers (Fig. 2B). We observed similar shifts in other sar-
comere components as well (38, 39), including myosin light-chain,
troponin, and tropomyosin isoforms, with components character-
istic of slow fibers (Myl2, Myl3, Myl6b, Myl10, Myl12a, Tnnc1,
Tnni1, Tnnt1, and Tpm3) being up-regulated and components
characteristic of fast fibers (Myl1, Mylpf, Tnnc2, Tnni2, Tnnt3, and
Tpm1) being down-regulated in Cdx2-cre–positive muscles. More-
over, expression levels of myosin light-chain kinase isoforms also
tracked with these fiber type shifts, with Mylk3 (slow fibers) and
Mylk2 (fast fibers) being up-regulated and down-regulated, re-
spectively. Finally, we observed up-regulation of certain sarcomere
protein isoforms not typically expressed in adult skeletal muscle,
includingMyh8 (neonatal),Myl4 (embryonic), Tnnt2 (cardiac), and
Tpm2 (cardiac), raising the possibility that there might be en-
hanced regeneration occurring in Cdx2-cre–positive muscles. We
did not, however, observe any increase in the number of centrally
located nuclei in muscles of Cdx2-cre–positive mice. Also consis-
tent with the histological changes were the results of pathway
analysis of the entire set of differentially expressed transcripts in
Cdx2-cre–positive muscles. Although no enriched pathways were
identified among the 234 down-regulated transcripts, 25 enriched
pathways were identified among the 399 up-regulated transcripts.
Strikingly, of the 8 enriched pathways comprising the greatest
number of genes, 7 corresponded to pathways involved in lipid
metabolism (Fig. 3C). These pathways encompassed a total of
40 up-regulated genes, 36 of which encode enzymes directly in-







Fig. 1. Effect of Fst mutant alleles on skeletal muscle. (A) Weights of gastrocnemius muscles versus Fst RNA expression levels in mice carrying various
combinations of Fstmutant alleles. Numbers are normalized to values for Fst+/+ muscles. RNA expression levels were measured by qPCR (n = 3 mice per group),
and muscle weights were taken from the data in Table 1. (B) Plasma FST levels in mice carrying various Fst mutant alleles with or without Myl1-cre or Cdx2-cre
transgenes (n = 4 per group). (C) Relative weights of pectoralis (red), triceps (gray), quadriceps (blue), and gastrocnemius/plantaris (green) muscles in mice
carrying various Fst mutant alleles with or without Myl1-cre. Numbers are expressed as percent increase/decrease relative to Fst+/+ mice and were calculated
from the data shown in Table 1. (D) Relative weights of muscles of Fstfl/− mice in the absence (blue bars) or presence (orange bars) of Cdx2-cre. Numbers are
expressed as percent increase/decrease relative to Fst+/+ mice and were calculated from the data shown in Table 1. G, gastrocnemius; P, pectoralis; Q,
quadriceps; T, triceps. aP < 0.001, bP < 0.05 versus Cdx2-cre–negative mice. (E) Distribution of fiber sizes in gastrocnemius muscles of F66 and Fst+/+ mice
(Upper) or Fstfl/−; Cdx2-cre–negative and –positive mice (Lower). Fiber diameters were measured in muscles isolated from three mice (250 fibers per mouse)
and pooled for plotting. (F) Plasma MSTN levels in Fstfl/−; Cdx2-cre–negative and –positive mice (n = 8 per group). Error bars represent standard error of the
mean (SEM). M, males; F, females.
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expression profiles in Cdx2-cre–positive muscles were consistent
with changes that we observed on histological examination of the
muscles.
A considerably larger number of differentially expressed genes
were identified in RNA-seq analysis of F66 muscles, with
2,274 up-regulated and 2,666 down-regulated transcripts com-
pared with wild-type muscles (SI Appendix, Fig. S1). Among the
down-regulated transcripts in F66 muscles were 75 that were
oppositely regulated (i.e., up-regulated) in Cdx2-cre–positive
mice. Pathway analysis of this subset of 75 genes identified three
enriched pathways, namely thermogenesis, the tricarboxylic acid
(TCA) cycle, and oxidative phosphorylation. These three enriched
pathways, which comprised overlapping sets of genes, included a
total of 17 genes whose functions were consistent with the shift
toward oxidative fibers seen in Cdx2-cre–positive mice and shift
toward glycolytic fibers seen in F66mice (Table 3). Among the up-
regulated transcripts in F66 muscles were 101 that were oppositely
regulated (i.e., down-regulated) in Cdx2-cre–positive mice. Pathway
Table 1. Effect of the targeting Fst on muscle weights
n Pectoralis, mg Triceps, mg Quadriceps, mg Gastrocnemius, mg
Males
Fstflox/flox 37 100.3 ± 1.8* 125.8 ± 2.1* 256.6 ± 3.9* 176.2 ± 2.3*
Fst+/flox 17 89.8 ± 1.9* 112.4 ± 2.7* 236.8 ± 4.8* 163.0 ± 3.6*
Fstflox/− 21 80.9 ± 1.1* 101.2 ± 1.7 204.5 ± 2.8 147.2 ± 1.5†
Fst+/+ 17 71.9 ± 2.0 96.1 ± 2.4 195.2 ± 5.7 136.1 ± 3.5
Fst+/− 9 58.2 ± 2.3* 77.7 ± 3.3* 150.9 ± 4.7* 109.8 ± 3.3*
Fstflox/flox + Myl1-cre 20 97.7 ± 2.0 120.5 ± 1.8 249.8 ± 4.2 175.1 ± 2.7
Fst+/flox + Myl1-cre 17 83.8 ± 2.3‡ 107.9 ± 2.6 222.1 ± 5.2‡ 155.9 ± 3.1
Fstflox/− + Myl1-cre 8 72.4 ± 2.0§ 93.3 ± 2.8‡ 190.1 ± 4.2§ 140.1 ± 3.2
Fstflox/− + Cdx2-cre 12 85.8 ± 1.6‡ 108.3 ± 2.9‡ 101.0 ± 3.7{ 70.0 ± 3.1{
Females
Fstflox/flox 37 65.8 ± 1.2* 91.5 ± 1.4* 192.8 ± 3.3* 133.6 ± 2.2*
Fst+/flox 25 60.4 ± 1.3* 84.1 ± 1.5* 179.8 ± 3.2* 123.6 ± 1.9*
Fstflox/− 30 55.6 ± 0.9* 79.2 ± 1.0* 164.3 ± 1.7* 118.2 ± 1.2*
Fst+/+ 28 44.3 ± 1.0 67.1 ± 0.9 138.8 ± 2.3 96.6 ± 1.3
Fst+/− 14 34.3 ± 1.4* 55.2 ± 1.3* 108.3 ± 3.2* 78.5 ± 2.5*
Fstflox/flox + Myl1-cre 22 56.7 ± 1.3{ 86.4 ± 1.4‡ 183.5 ± 3.0‡ 129.4 ± 2.1
Fst+/flox + Myl1-cre 21 57.6 ± 1.0 82.3 ± 1.2 172.2 ± 2.2 119.6 ± 1.8
Fstflox/− + Myl1-cre 14 44.8 ± 1.2{ 73.1 ± 2.0‡ 150.3 ± 4.1§ 111.5 ± 3.0‡
Fstflox/− + Cdx2-cre 10 59.9 ± 1.9‡ 81.3 ± 1.5 76.4 ± 3.2{ 50.2 ± 1.8{
*P < 0.001 vs. Fst+/+.
†P < 0.01 vs. Fst+/+.
‡P < 0.05 vs. cre−.
§P < 0.01 vs. cre−.
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Fig. 2. Fiber type shifts in Fstmutant mice. (A) Percent type I, type IIa, and type IIb fibers in gastrocnemius and triceps muscles of Fstfl/−; Cdx2-cre and F66mice
(n = 3 per group). (B) Relative RNA expression levels for genes encoding sarcomeric protein isoforms and kinases. Numbers were determined by RNA-seq
analysis and are presented as the log2 ratio of values obtained for Cdx2-cre–positive to Cdx2-cre–negative (n = 9 per group). Blue, slow isoforms; orange, fast
isoforms; green, developmental and cardiac isoforms. Error bars represent SEM. aP < 0.001, bP < 0.01, cP < 0.05.
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analysis of this subset of 101 genes identified seven enriched path-
ways, encompassing an overlapping set of 38 genes. Among these 38
genes were Rps6kb1, encoding ribosomal protein S6 kinase B1,
which plays an important role in regulating protein synthesis, three
protooncogenes (Braf, Mras, and Nras), and genes encoding 13
components of the cytoskeleton and extracellular matrix, including
ankyrin 1, radixin, sarcoglycan alpha, decorin, thrombospondin 1, 2
integrin subunits, and 6 collagen chains (SI Appendix, Table S3).
The dramatic effects of FST loss seen in the quadriceps and
gastrocnemius of Fstflox/−; Cdx2-cre mice clearly show the im-
portant role that FST plays in regulating muscle size and struc-
ture. The effects seen in these mice could result either from loss
of local action by FST or from loss of systemic action by FST, or
both. Indeed, circulating levels of FST were decreased by 26 and
21% in Fstflox/−; Cdx2-cre males and females, respectively (Fig.
1B), reflecting the fact that FST production is eliminated in the
posterior region of the body in these mice. Given that the phe-
notype of Fstflox/−; Cdx2-cre mice is much more pronounced than
that seen in Fst+/− mice, which exhibit decreases in circulating
FST levels by about 50%, and in Fstflox/−; Myl1-cre mice, which
exhibit decreases of slightly more than 20%, it seemed unlikely
that systemic loss of FST could explain the greater effects seen in
the quadriceps and gastrocnemius muscles of Fstflox/−; Cdx2-cre
mice compared with these other mice. To investigate further this
question of local versus systemic modes of FST action, we ana-
lyzed muscles located in the anterior region of the animal where
Cdx2-cre is not expressed. In contrast to the dramatic decreases
in muscle weights seen in the posterior muscles, weights of an-
terior muscles (pectoralis and triceps) were not decreased in
Fstflox/−; Cdx2-cre mice (Fig. 1D and Table 1), implying that FST
produced in the anterior region of the body is sufficient to
maintain FST function in the anterior region even with the lower
circulating levels of FST protein. Similarly, unlike the gastroc-
nemius, the triceps muscles showed no differences in fiber type
distribution between Cdx2-cre–positive and cre-negative mice
(Fig. 2A). Moreover, Nile red staining of triceps muscles showed
no differences in fluorescence intensity between Cdx2-cre–positive
and cre-negative mice, suggesting that the accumulation of fat
droplets seemed to be restricted to the posterior region of the
mice in which Cdx2-cre is expressed (Fig. 3B). Finally, whereas
RNA-seq analysis of the gastrocnemius muscles identified a total
of 633 differentially expressed transcripts between Cdx2-
cre–positive and cre-negative mice, RNA-seq analysis of triceps
muscles revealed no differences between Cdx2-cre–positive com-
pared with cre-negative mice with an adjusted P value less than
0.05. In contrast, fiber type shifts toward glycolytic type IIb fibers
and reductions in fat accumulation were seen in both the triceps
and gastrocnemius muscles of F66 mice (Figs. 2A and 3B),
reflecting the fact that the Fst-overexpressing transgene was
expressed in skeletal muscles throughout the body. The simplest
interpretation of all these data is that FST acts predominantly, if
not exclusively, in a local manner to regulate muscle size, fiber
type, and lipid accumulation.
Analysis of the anterior muscles did reveal, however, some
systemic effects of targeting Fst in the posterior region. In par-
ticular, instead of muscle weights being reduced in the anterior
region of Fstflox/−; Cdx2-cre mice, weights of the pectoralis and
triceps muscles actually exhibited small but significant increases
compared with cre-negative mice (Fig. 1D and Table 1), which is
the opposite of what would be expected upon loss of FST. Al-
though this effect on anterior muscles, which was seen in both
males and females, could reflect a variety of physiological changes
occurring in the animal as a result of loss of FST production in the
posterior half of the body, we believe that a possible explanation is
that circulating levels of MSTN in Cdx2-cre–positive mice are
reduced by ∼35 to 40% compared with cre-negative mice (Fig.
1F). Given thatMstnRNA levels were unchanged in both anterior
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Fig. 3. Lipid accumulation in Fst mutant mice. (A) Oil red O stains of gas-
trocnemius sections of Fstfl/−; Cdx2-cre–negative and –positive mice. (B)
Fluorescence intensity of Nile red–stained sections of gastrocnemius and
triceps muscles of Fstfl/−; Cdx2-cre and F66mice. Numbers represent means of
measurements taken from Fstfl/−; Cdx2-cre–negative, Fstfl/−; Cdx2-
cre–positive, wild-type, and F66 mice, with n = 5, 5, 7, and 7 mice, respec-
tively, and with four representative sections analyzed for each mouse. (C)
Up-regulated pathways identified by RNA-seq analysis of gastrocnemius
muscles isolated from Fstfl/−; Cdx2-cre–positive compared with cre–negative
mice (n = 9 per group). Error bars represent SEM.
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cre-negative mice (SI Appendix, Fig. S2), the drop in circulating
MSTN levels likely reflects the reduced amount of total muscle
mass in Fstflox/−; Cdx2-cre mice. We have shown that skeletal
muscle is by far the predominant source of circulating MSTN
protein (22) and, in a previous study using a similar approach to
target an Mstnflox allele in the posterior region of the body with
Cdx2-cre, we showed that MSTN acts to regulate muscle mass
both by autocrine/paracrine and by endocrine modes of signaling
(40). Hence, the reduction in circulating MSTN in Fstflox/−; Cdx2-
cre mice would be predicted to compensate partially for reduced
FST with respect to control of muscle mass and, in anteriorly lo-
cated muscles, lower circulating MSTN levels would be expected
to cause increases in muscle growth.
In addition to the key role that the MSTN/activin A signaling
pathway plays in regulating muscle mass, several studies have
shown that this regulatory system is also important in the regu-
lation of bone structure and bone density. Specifically, systemic
administration of a decoy receptor consisting of the extracellular
domain of ACVR2B fused to an immunoglobulin Fc domain has
been shown to cause significant increases in bone mineral density
and various microcomputed tomography (micro-CT) parame-
ters, such as bone volume/total volume (BV/TV), connectivity
density, and trabecular number (41–45), which are also seen to a
milder degree upon targeting Acvr2 and Acvr2b specifically in
osteoblasts in vivo (44). Given that FST is capable of blocking
the activities of ligands signaling through activin type 2 receptors,
we investigated the effects of manipulating Fst expression levels
on bone density and structure. As shown in SI Appendix, Tables
S4–S8 and Fig. 4 A and B, micro-CT analysis of femurs, humeri,
and L4 and L5 vertebrae showed opposite trends in Fstflox/flox and
Fst+/− mice in comparison with wild-type mice. Specifically, pa-
rameters such as bone volume, bone surface, BV/TV, connec-
tivity density, trabecular number, trabecular thickness, and bone
mineral density were generally higher in bones of Fstflox/flox mice
and were generally lower in bones of Fst+/− mice compared with
those of wild-type mice. Many, though not all, of the differences
Table 2. Expression levels of genes identified in enriched pathways related to lipid metabolism
that are up-regulated in Cdx2-cre–positive (relative to cre-negative) gastrocnemius muscles
Gene Protein Log2 ratio P
Acaa2 Acetyl-coA acyltransferase 2 +0.66 4.9E-7
Acadl Acyl-coA dehydrogenase long chain +0.73 4.4E-7
Acadm Acyl-coA dehydrogenase medium chain +0.76 7.6E-6
Acadvl Acyl-coA dehydrogenase very long chain +0.40 1.0E-3
Acat1 Acetyl-coA acetyltransferase 1 +0.46 9.2E-5
Acot1 Acyl-coA thioesterase 1 +0.47 1.2E-3
Acot2 Acyl-coA thioesterase 2 +0.91 1.4E-4
Acsl1 Acyl-coA synthetase long-chain family member 1 +0.79 3.3E-4
Agpat2 1-Acylglycerol-3-phosphate O-acyltransferase 2 +0.79 1.8E-3
Agpat3 1-Acylglycerol-3-phosphate O-acyltransferase 3 +0.36 3.8E-3
Aldh9a1 Aldehyde dehydrogenase 9 family member A1 +0.62 2.5E-4
Amacr Alpha-methylacyl-coA racemase +0.27 2.1E-3
Cat Catalase +0.46 3.3E-3
Cd36 Cluster of differentiation 36 (fatty acid translocase) +0.69 1.0E-6
Cpt1b Carnitine palmitoyltransferase 1B +0.31 1.3E-3
Cpt2 Carnitine palmitoyltransferase 2 +0.35 7.5E-6
Dgat2 Diacylglycerol O-acyltransferase 2 +1.21 2.4E-5
Dhrs4 Dehydrogenase/reductase 4 +0.83 3.7E-7
Ech1 Delta(3,5)-delta(2,4)-dienoyl-coA isomerase +0.54 5.6E-6
Echs1 Enyl-coA hydratase, short chain 1 +0.56 7.7E-5
Eci1 Enol-coA delta isomerase 1 +0.46 2.5E-4
Eci2 Enol-coA delta isomerase 2 +0.40 7.5E-7
Ephx2 Epoxide hydrolase 2 +0.75 1.8E-7
Fabp3 Fatty acid–binding protein 3 +1.15 3.7E-8
Gk Glycerol kinase +0.66 1.8E-3
Hadh 3-Hydroxyacyl-coA dehydrogenase +0.72 6.2E-5
Hadha Hydroxyacyl-coA dehydrogenase trifunctional multienzyme complex
subunit alpha
+0.70 4.5E-4
Hadhb Hydroxyacyl-coA dehydrogenase trifunctional multienzyme complex
subunit beta
+0.72 6.2E-5
Idh2 Isocitrate dehydrogenase [NADP(+)] 2 +1.23 6.7E-9
Lpl Lipoprotein lipase +1.03 1.8E-7
Mlycd Malonyl-coA decarboxylase +0.52 4.9E-4
Nudt7 Peroxisomal coenzyme A diphosphatase +0.56 3.7E-6
Pex6 Peroxisomal biogenesis factor 6 +0.42 2.2E-4
Phyh Phytanoyl-coA 2-hydroxylase +0.35 8.0E-4
Pla2g12a Phospholipase A2 group XIIA +0.89 2.9E-9
Plin5 Perilipin-5 +1.44 6.7E-8
Plpp1 Phospholipid phosphatase 1 +0.27 5.9E-4
Plpp2 Phospholipid phosphatase 2 +0.87 1.8E-3
Pnpla2 Patatin-like phospholipase domain-containing 2 +0.45 6.4E-5
Slc27a1 Solute carrier family 27 member 1 (long-chain fatty acid transport
protein 1)
+0.72 7.2E-6
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observed among the different genotypes were statistically sig-
nificant, and the general trends were clearly evident in consid-
ering data from both males and females as well as from multiple
bones. Hence, as in the case of muscle mass, varying levels of Fst
expression also affected bone structure, with reduced levels of
Fst expression leading to reduced bone density, demonstrating
that FST plays an important, dose-dependent role in regulating
bone homeostasis.
To determine whether FST acts locally versus systemically to
regulate bone density, we analyzed the bones of Fstflox/−; Cdx2-cre
mice. We first carried out dual-energy X-ray absorptiometer
(DXA) analysis in which we compared different regions of the
body in Cdx2-cre–positive versus cre-negative mice. As shown in
SI Appendix, Table S9, bone density by DXA was significantly
lower in Cdx2-cre–positive compared with cre-negative mice in
examining bones located in the posterior region of the body,
including left and right femurs as well as L2/L3 and L4/L5 ver-
tebrae. In contrast, bone density in either the left or right hu-
merus was similar between Cdx2-cre–positive and cre-negative
mice. Hence, bone density appeared to be affected in bones lo-
cated in the posterior but not anterior region of the body. To
examine bone structure in greater detail, we carried out micro-CT
analysis of various bones isolated from these mice. Analysis of
femurs showed that bone volume, bone surface, BV/TV, connec-
tivity density, trabecular number, trabecular thickness, and bone
mineral density were all significantly reduced in Cdx2-cre–positive
compared with cre-negative mice (Fig. 4C and SI Appendix, Tables
S10 and S11). These decreases were not seen, however, in micro-
CT analysis of humeri isolated from these mice, and some of these
parameters, such as bone volume, bone surface, BV/TV, and
connectivity density, were even slightly increased in Cdx2-
cre–positive compared with cre-negative male mice. Although we
do not understand the basis for these small increases, the fact that
decreases in bone density were seen in femurs but not in humeri of
Cdx2-cre–positive mice suggests that FST acts locally to regulate
bone structure.
The effects on bone seen upon manipulating expression levels
of Fst are consistent with prior studies showing that pharmaco-
logical inhibition of signaling by systemic administration of the
ACVR2B/Fc decoy receptor can cause dramatic changes in bone
structure, including increases in bone density, BV/TV, connec-
tivity density, and trabecular number and thickness (41–45).
Moreover, targeting Acvr2 either alone or in combination with
Acvr2b in osteoblasts in vivo also leads to increases in femoral
BV/TV and trabecular number (44). The effects of targeting
Acvr2 and Acvr2b in osteoblasts, however, were milder than
those seen following treatment with ACVR2B/Fc, and treatment
with ACVR2B/Fc was shown to cause even further increases in
these parameters in mice in which both receptors were targeted
in osteoblasts. These findings imply either that targeting the two
activin type 2 receptors ACVR2 and ACVR2B may not be suf-
ficient to completely block signaling by key ligands to osteoblasts
or that osteoblasts may not be the sole target for these ligands
with respect to regulation of bone homeostasis. To address the
former possibility, we examined the effect of targeting ALK4 and
ALK5, which are the two type 1 receptors utilized by MSTN and
activin A in regulating skeletal muscle mass (22). Specifically, we
used mice carrying floxed alleles for Alk4 and Alk5 to examine
the effect of simultaneously targeting these type 1 receptors
utilizing the osteocalcin-cre (Oc-cre) transgene, which has been
shown to be expressed specifically in osteoblasts (46). For com-
parison, we also analyzed mice in which we simultaneously tar-
geted Acvr2 and Acvr2b using the same Oc-cre transgene.
By micro-CT analysis, very few differences were detected in
femurs, humeri, or L5 vertebrae of Acvr2flox/flox; Acvr2bflox/flox;
Oc-cre mice compared with cre-negative mice in either males or
females (Fig. 5A and SI Appendix, Tables S12–S14). In contrast,
the effects on bone structure in Alk4flox/flox; Alk5flox/flox; Oc-cremice
were readily apparent upon visual inspection of the micro-CT
images (Fig. 5B), and nearly all of the micro-CT parameters
showed dramatic differences compared with cre-negative control
mice in all of the bone groups analyzed in both males and females
(Fig. 5A and SI Appendix, Tables S12–S14). In females, for ex-
ample, BV/TV was increased by 12- to 13-fold and bone mineral
density was increased by 8- to 9-fold in humeri, femurs, and L5
vertebrae of Alk4flox/flox; Alk5flox/flox; Oc-cre mice compared with
cre-negative mice. Hence, targeting signaling specifically in oste-
oblasts leads to massive increases in bone volume and density, with
the effects of targeting the two type 1 receptors being much more
pronounced compared with targeting the two type 2 receptors.
Finally, we carried out genetic studies investigating whether
MSTN and activin A are the key ligands signaling through ALK4
and ALK5 to regulate bone. Previous studies have shown that
bones of Mstn−/− mice have altered morphology and increased
density (for a review, see ref. 47), suggesting that MSTN plays
either a direct or indirect role in regulating bone structure. The
Table 3. Expression levels of genes identified in enriched pathways that are both up-regulated in Cdx2-cre–positive (relative to
cre-negative) and down-regulated in F66 (relative to wild-type) gastrocnemius muscles
Gene Protein Cdx2-cre log2 ratio P F66 log2 ratio P
Adcy6 Adenylate cyclase 6 +0.25 1.7E-2 −0.48 1.6E-5
Atp5b ATP synthase F1 subunit beta +0.22 2.1E-2 −0.21 3.2E-2
Atp5c1 ATP synthase F1 subunit gamma +0.16 9.3E-3 −0.30 3.9E-6
Atp5pb ATP synthase peripheral stalk-membrane subunit B +0.28 5.3E-4 −0.22 6.2E-3
Coa4 Cytochrome C oxidase assembly factor 4 homolog +0.45 4.9E-3 −0.36 4.1E-2
Cox5a Cytochrome C oxidase subunit 5A +0.33 1.5E-2 −0.36 8.6E-3
Cox7a2l Cytochrome C oxidase subunit 7A2-like +0.32 2.5E-6 −0.16 1.8E-2
Idh3b Isocitrate dehydrogenase [NAD(+)] 3 noncatalytic subunit beta +0.29 1.2E-3 −0.23 9.8E-3
Idh3g Isocitrate dehydrogenase [NAD(+)] 3 noncatalytic subunit gamma +0.16 1.1E-2 −0.37 4.6E-8
Lipe Lipase E, hormone sensitive type +0.38 2.2E-2 −1.10 4.2E-9
Mdh2 Malate dehydrogenase 2 +0.15 3.2E-2 −0.24 1.2E-3
Ndufaf4 NADH-ubiquinone oxidoreductase complex assembly factor-4 +0.18 3.2E-2 −0.32 3.0E-4
Ndufv1 NADH-ubiquinone oxidoreductase core subunit V1 +0.26 1.7E-2 −0.24 2.6E-2
Pdhb Pyruvate dehydrogenase E1 subunit beta +0.27 2.5E-3 −0.19 3.1E-2
Prkag1 Protein kinase AMP-activated noncatalytic subunit gamma-1 +0.22 2.5E-3 −0.28 1.8E-4
Sdhc Succinate dehydrogenase complex subunit C +0.30 4.7E-3 −0.30 4.8E-3
Uqcrc1 Ubiquinol-cytochrome C reductase core protein 1 +0.19 3.4E-2 −0.24 1.1E-2
These genes were identified as corresponding to enriched pathways for thermogenesis, the TCA cycle, and oxidative phosphorylation.
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effects ofMstn loss on parameters such as bone density, however,
have been reported to be relatively mild compared with the ef-
fects that we have observed targeting the type 1 receptors in
osteoblasts. Therefore, we examined the effect of loss of Inhba
(encoding the βA-subunit of activin A and activin AB) on bone
structure. Because complete loss of Inhba leads to embryonic
lethality (48), we examined the effect of targeting Inhba in a
regionally restricted manner using the Cdx2-cre transgene by
targeting an Inhbaflox allele only in the posterior region of the
animal. In order to maximize the potential effects on bone, we
simultaneously targeted Mstn using an Mstnflox allele in con-
junction with the Cdx2-cre transgene.
By DXA analysis, lean body mass was significantly increased in
Mstnflox/flox; Inhbaflox/flox; Cdx2-cre mice compared with that of
cre-negative mice, which could be attributed almost entirely to
increases in the posterior half of the animals (Fig. 6A). Analysis
of individual muscles revealed that weights of the quadriceps and
gastrocnemius muscles were increased by 111 and 185%, respec-
tively, compared with cre-negative mice (Fig. 6B). In a previous
study, we showed that targetingMstn alone in the posterior half of
the animal using this same approach led to increases in weights of
the quadriceps and gastrocnemius muscles by 73 and 85%, re-
spectively (40). Hence, targeting Mstn and Inhba together led to
much more substantial increases in muscle mass compared with
targeting Mstn alone, consistent with prior studies documenting
that activin A is capable of cooperating with MSTN to limit
muscle growth (20, 24–27). Targeting Mstn and Inhba also led to
significant changes in bone structure. As in the case of muscle, by
DXA analysis, bone mineral density was increased in the posterior
half ofMstnflox/flox; Inhbaflox/flox; Cdx2-cre mice (Fig. 6A). By micro-
CT analysis, parameters such as BV/TV, trabecular number, and
bone mineral density were all significantly increased in femurs of
Mstnflox/flox; Inhbaflox/flox; Cdx2-cre mice (Fig. 6C); the effects,
however, were significantly milder than those seen upon targeting
Alk4 and Alk5.
To determine whether these ligands act in an autocrine/
paracrine or endocrine manner to regulate muscle and bone, we
analyzed tissues isolated from the anterior region of Mstnflox/flox;
Inhbaflox/flox; Cdx2-cre mice. We previously showed that targeting
Mstn in the posterior region leads not only to significant in-
creases in weights of posteriorly located muscles but also to
modest increases in weights of anteriorly located muscles (40).
As shown in Fig. 6B, weights of pectoralis and triceps muscles,
which are located in the anterior region, were increased by ∼25%
in Mstnflox/flox; Inhbaflox/flox; Cdx2-cre mice compared with cre-
negative mice, consistent with a systemic role of circulating
MSTN and/or activin A in regulation of muscle mass. In contrast,
although we observed trends toward increased BV/TV, trabecular
number, and bone mineral density in humeri of male mice (Fig.
6C), none of these differences were significant, and these param-
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Fig. 4. Effect of Fst mutant alleles on bone. (A and B) Micro-CT analysis of (A) femurs and (B) L4 and L5 vertebrae of Fstflox/flox, Fst+/+, and Fst+/− mice. aP <
0.001, bP < 0.01, cP < 0.05. (C) Micro-CT analysis of femurs and humeri isolated from Fstfl/−; Cdx2-cre–negative and –positive mice. Numbers of mice per group
are shown below. Error bars represent SEM.
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these ligands appear to act predominantly locally to regulate bone
structure.
Discussion
Here, we present the results of genetic studies demonstrating a
critical role for FST in regulating both skeletal muscle and bone
homeostasis. Using an allelic series corresponding to varying Fst
RNA expression levels and circulating FST protein levels, we
show that FST acts in an exquisitely dose-dependent manner to
regulate both muscle mass and bone density. With respect to
muscle, reductions in FST levels lead not only to decreased muscle
mass but also a shift toward oxidative fibers and increased intra-
muscular lipid accumulation, and, conversely, increased FST levels
lead to increased muscle mass, a shift toward glycolytic fibers, and
reduced lipid accumulation. With respect to bone, altered levels of
FST lead to significant changes in bone structure, with reductions
in FST levels leading to decreased bone density, decreased BV/
TV, decreased trabecular number, and decreased trabecular
thickness. Moreover, by employing a genetic strategy to target Fst
expression only in the posterior region of the animal, we show that
the effects of Fst loss are mostly restricted to the posterior region,
implying that FST acts predominantly in a local manner in both
muscle and bone. Our findings suggest that locally produced FST,
most likely the FST288 isoform, plays a much more important role
than circulating FST, at least with respect to regulation of muscle
and bone. In the case of muscle, our results targeting Fst in
myofibers suggest that although myofiber-derived FST does play a
role in the overall regulation of muscle mass, FST derived from
other cell types plays a more substantial role. Additional studies
will be required to identify the key sources of FST for both muscle
and bone, and our studies suggest that these sources must be local
to these tissues. We believe that these findings have important
implications both with respect to understanding the physiological
mechanisms by which muscle and bone homeostasis are regulated
by members of the TGF-β family and with respect to the inter-
pretation of studies attempting to correlate circulating levels of
FST with various disease states in humans.
Given that the only known mode of action of FST is to bind to
and inhibit the activities of members of the TGF-β family of
secreted signaling molecules, the effects of altered levels of FST
seen in our studies almost certainly reflect altered levels of sig-
naling by various TGF-β family members that are normally tar-
gets for FST. Previous studies have demonstrated that blocking
the activities of certain TGF-β ligands using a decoy form of the
ACVR2B/Fc receptor can lead to dramatic increases in muscle
mass (20) and bone density (41–45), implying that the key ligands
involved in regulating muscle and bone are likely to be ones
capable of binding both FST and ACVR2B/Fc. Two such ligands
are MSTN and activin A, and extensive genetic and pharmaco-
logical studies have documented the critical role that MSTN and
activin A play in regulating muscle growth (1, 20, 24–27). Here,
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Fig. 5. Effect of targeting type 2 and type 1 receptors in osteoblasts. (A) Micro-CT analysis of humeri, femurs, and L5 vertebrae of Acvr2flox/flox; Acvr2bflox/flox;
Oc-cre–negative (n = 9 females and 9 males), Acvr2flox/flox; Acvr2bflox/flox; Oc-cre–positive (n = 9 females and 6 males), Alk4flox/flox; Alk5flox/flox; Oc-cre–negative
(n = 6 females and 9 males), and Alk4flox/flox; Alk5flox/flox; Oc-cre–positive (n = 6 females and 7 males) mice. aP < 0.001, bP < 0.01, cP < 0.05. (B) Representative
micro-CT images. Error bars represent SEM.
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two ligands simultaneously can lead to massive muscle growth.
Furthermore, by targeting these ligands only in the posterior
region of mice, we observed systemic effects in terms of muscle
mass increases in anteriorly located muscles. These findings
taken together with results of similar studies in which we tar-
geted Mstn alone in the posterior region (40) demonstrate that
MSTN and activin A each act in both an autocrine/paracrine and
an endocrine manner to regulate muscle mass. In this regard, we
observed that targeting Fst only in the posterior region led to
reduced mass of posteriorly located muscles but actually had the
reverse effect of slightly increasing mass of anteriorly located
muscles, which is the opposite of what would be predicted for
increased signaling by MSTN and/or activin A. We believe that
this effect in anterior muscles is most likely the result of the
dramatically reduced muscle mass in the posterior region of
Fstflox/−; Cdx2-cre mice leading to decreased circulating levels of
MSTN, which through its endocrine mode of action then affects
muscles throughout the body. In contrast to muscle, less is known
regarding the key ligands being targeted by FST and ACVR2B/
Fc in bone, as definitive genetic studies examining the effects of
targeting this subgroup of ligands in bone have not yet been
reported. Here, we show that targeting MSTN and activin A
leads not only to increases in muscle mass but also to increases in
bone density. Although the effects of targeting these two ligands
were significant, the magnitude of the effects was considerably
lower than what we were able to achieve by targeting the receptors
for these ligands, implying that other ligands utilizing these re-
ceptors must also play important roles in regulating bone ho-
meostasis. Moreover, unlike in the case of muscle, we were unable
to detect systemic effects on bone from targeting these ligands in a
regionally restricted manner, suggesting that these ligands act
predominantly locally to regulate bone density.
Whatever the key ligands may be in bone, targeting signaling
in osteoblasts is sufficient to cause changes in bone structure,
including increases in bone mass and density, demonstrating that
osteoblasts are direct targets for signaling by these ligands in
vivo. It is also possible that changes in muscle mass in some of
these studies could also indirectly affect bone structure, for ex-
ample as a result of changes in mechanical forces exerted by the
muscles or changes in release of myokines that signal to bone. In
a previous study, we showed that by targeting Acvr2 and Acvr2b
in myofibers, we were able to increase muscle mass by 40 to 70%
without observing any changes in bone structure by micro-CT
analysis (22), suggesting that most, if not all, of the changes
that we observed in bone structure described here as a result of
pathway inhibition likely reflect modulation of signaling by li-
gands directly to bone. It is certainly possible, however, that in-
direct effects from reduced muscle mass in Fst-targeted mice
may secondarily affect bone by either mechanism. Although we
observed minimal effects of targeting the two type 2 receptors,
ACVR2 and ACVR2B, in osteoblasts, the effects on bone struc-
ture and density were extensive upon targeting the two type 1
receptors, ALK4 and ALK5. The increases in parameters such as
BV/TV and bone mineral density seen upon targeting ALK4 and
ALK5 were quite remarkable, reaching levels of 12- to 13-fold in
the case of BV/TV and 8- to 9-fold in the case of bone mineral
density. We previously reported a similar discrepancy in the
magnitude of muscle mass increases resulting from targeting these
receptors in myofibers (22). In particular, we observed significant
increases in muscle mass upon targeting ACVR2 and ACVR2B
but substantially greater increases in muscle mass (up to threefold)
upon targeting ALK4 and ALK5. The differential effects observed
upon targeting type 1 versus type 2 receptors in both bone and
muscle suggest that the simple model that combinations of
ACVR2 and ACVR2B with ALK4 and ALK5 mediate all of the
signaling by key TGF-β–related ligands in these tissues is likely
incomplete. One possible explanation could be that this model is

























































































































Fig. 6. Effect of targeting Mstn and Inhba in the posterior half of mice. (A)
Lean body mass (Upper) and bone mineral density (Lower) of Mstnflox/flox;
Inhbaflox/flox; Cdx2-cre–negative (n = 8) and –positive (n = 8) mice by DXA
analysis. Data are shown for the whole body or just the anterior or posterior
half of the body. (B) Muscle weight increases in Mstnflox/flox; Inhbaflox/flox;
Cdx2-cre mice relative to cre-negative control mice. P, pectoralis; T, triceps;
Q, quadriceps; G, gastrocnemius. (C) Micro-CT analysis of humeri and femurs
of Mstnflox/flox; Inhbaflox/flox; Cdx2-cre. Error bars represent SEM. aP < 0.001,
bP < 0.01, cP < 0.05.
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some other mechanism. An alternative explanation could be that
the spectrum of ligands being blocked by targeting ACVR2 and
ACVR2B may be different from those being blocked by targeting
ALK4 and ALK5. For example, TGF-β is also known to signal
through ALK5, but TGF-β utilizes a different type 2 receptor,
namely TGFBR2, to couple to ALK5, raising the possibility that
loss of TGF-β signaling may have contributed to the effects seen
upon targeting ALK5. Similarly, it is known that certain BMPs are
capable of utilizing activin type 2 receptors for signaling, and BMP
signaling has been shown to have the opposite effect of MSTN/
activin A signaling in both muscle (49, 50) and bone (for a review,
see ref. 51). Hence, it is possible that reduced levels of BMP
signaling may have partially compensated for loss of MSTN/activin
A signaling resulting from targeting Acvr2 and Acvr2b in muscle
and/or bone. In this regard, it is possible that levels of BMP ac-
tivity may also have been affected in mice with altered FST levels,
as FST is capable of binding and inhibiting BMPs as well.
Further study of this regulatory system will be critical not only
for understanding the mechanisms underlying the control of
tissue growth but also for developing the most optimal strategies
to target this signaling pathway for clinical applications, such as
to treat bone loss and muscle loss. In this regard, it will be im-
portant to elucidate the precise identities of the key ligands in-
volved in regulating bone homeostasis as well as the precise
receptors and other components utilized by these ligands for
signaling in both muscle and bone. Moreover, FST is only one of
multiple extracellular binding proteins that are capable of binding
and inhibiting these ligands, and although considerable work has
been done in examining the roles of these binding proteins in
muscle, much less has been reported with respect to bone. Un-
derstanding the extent to which specific regulatory and signaling
components are shared between bone and muscle will be espe-
cially important given the extensive ongoing effort among phar-
maceutical and biotechnology companies to target this signaling
pathway to treat patients with muscle loss and metabolic diseases
(for a review, see ref. 52), as some of these therapeutic approaches
and agents could also be useful to treat bone loss, including
conditions characterized by comorbid bone and muscle loss.
The magnitude of the effect that we observed upon targeting
the type 1 receptors in osteoblasts reveals the enormous inherent
capacity for bone growth that is normally kept in check by this
signaling pathway, and in many respects these findings are
reminiscent of the massive increases in muscle mass that we
observed upon targeting these same receptors in myofibers (22).
These findings demonstrate that ligands capable of signaling
through these receptors normally function to limit growth of
muscle and bone and raise the question as to the extent to which
signaling through this pathway may also limit growth of other
tissues. Bullough originally proposed the term “chalone” to de-
scribe hypothetical circulating negative growth regulators that
function to control tissue size (53). MSTN seems to fulfill all the
essential criteria for a chalone for skeletal muscle (54, 55), and
our findings raise the possibility that a similar regulatory mech-
anism with shared signaling components may be operating in
other tissues as well.
Materials and Methods
All animal experiments were carried out in accordance with protocols that
were approved by the Institutional Animal Care and Use Committees at the
Jackson Laboratory, University of Connecticut School of Medicine, and Johns
Hopkins University School of Medicine. Mice carrying floxed alleles for Fst
(33), Acvr2 (44), Acvr2b (35), Alk4 (22), Alk5 (56), and Inhba (57) have been
described previously. Individual muscles were dissected and weighed from
both sides of 10-wk-old mice, and the average weight was used for each
muscle. Circulating protein levels were determined on acid-activated serum
samples by enzyme-linked immunosorbent assay using the LSBio F13187 Kit
(FST) and R&D Systems DGDF80 Kit (MSTN). Serial sections (15 μm) were cut
transversely through the widest point of the gastrocnemius and triceps
muscles using a cryostat. Fiber diameters were measured (as the shortest
distance across each fiber passing through the midpoint) from hematoxylin
and eosin–stained sections. Measurements were carried out on 250 fibers
per muscle, and all data for a given genotype were pooled. Fiber type
analysis was carried out using antibodies BA-D5, SC-71, and BF-F3 for myosin
heavy chains type I, IIa, and IIb, respectively (58), obtained from the Devel-
opmental Studies Hybridoma Bank developed under the auspices of the
National Institute of Child Health and Human Development and maintained
by the University of Iowa. Nile red staining was carried out as described (59).
Fluorescence was quantified using ImageJ on images taken with a Nikon Ti
Eclipse wide-field microscope. RNA-seq, DXA scan, and micro-CT analyses
were carried out as described previously (45). RNA extraction and analysis by
real-time qPCR were performed as described previously (40). Histological and
RNA-seq analyses were carried out on tissues isolated from male mice so that
comparisons could be made with F66mice, which carry an Fst-overexpressing
transgene located on the Y chromosome (24).
Data Availability.All study data are included in the article and/or SI Appendix.
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